《大行報告》摩通:潤啤(00291.HK)首席執行官斥65%酬金進行增持 顯示對前景信心
據聯交所資料,華潤啤酒(00291.HK)首席執行官侯孝海於本周一(11日)按每股39.489元,在場內增持華潤啤酒10萬股,摩根大通發表報告表示,侯孝海今次增持涉資共約51萬美元(相當於去年酬金65%),對比其2019年及2018年酬金各79萬美元及58萬美元。侯孝海在今次增持交易之前,已為華潤啤酒最大個人投資者,而且是六十大股份持有人。目前,其持有公司已發行股本0.03%。
該行認為,侯孝海今次增持行動影響正面,顯示其對集團的基本面及未來前景極具信心,料可受惠行業復甦,指華潤啤酒為該行在大中華地區消費股首選。該行予華潤啤酒「增持」評級及目標價45元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.